GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Thermo Fisher Scientific Inc (NYSE:TMO) » Definitions » Debt-to-Equity

TMO (Thermo Fisher Scientific) Debt-to-Equity : 0.72 (As of Sep. 2024)


View and export this data going back to 1980. Start your Free Trial

What is Thermo Fisher Scientific Debt-to-Equity?

Thermo Fisher Scientific's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $4,116 Mil. Thermo Fisher Scientific's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $31,197 Mil. Thermo Fisher Scientific's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $48,992 Mil. Thermo Fisher Scientific's debt to equity for the quarter that ended in Sep. 2024 was 0.72.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Thermo Fisher Scientific's Debt-to-Equity or its related term are showing as below:

TMO' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.51   Med: 0.72   Max: 0.89
Current: 0.72

During the past 13 years, the highest Debt-to-Equity Ratio of Thermo Fisher Scientific was 0.89. The lowest was 0.51. And the median was 0.72.

TMO's Debt-to-Equity is ranked worse than
74.87% of 191 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.27 vs TMO: 0.72

Thermo Fisher Scientific Debt-to-Equity Historical Data

The historical data trend for Thermo Fisher Scientific's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thermo Fisher Scientific Debt-to-Equity Chart

Thermo Fisher Scientific Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.60 0.63 0.86 0.78 0.75

Thermo Fisher Scientific Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.78 0.75 0.78 0.75 0.72

Competitive Comparison of Thermo Fisher Scientific's Debt-to-Equity

For the Diagnostics & Research subindustry, Thermo Fisher Scientific's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Thermo Fisher Scientific's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Thermo Fisher Scientific's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Thermo Fisher Scientific's Debt-to-Equity falls into.



Thermo Fisher Scientific Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Thermo Fisher Scientific's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Thermo Fisher Scientific's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Thermo Fisher Scientific  (NYSE:TMO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Thermo Fisher Scientific Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Thermo Fisher Scientific's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Thermo Fisher Scientific Business Description

Address
168 Third Avenue, Waltham, MA, USA, 02451
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (22%); and lab products and services, which includes CRO services (54%).
Executives
Marc N Casper officer: Senior Vice President C/O THERMO FISHER SCIENTIFIC, 168 THIRD AVENUE, WALTHAM MA 02451
Gianluca Pettiti officer: Executive Vice President C/O BUTTERFLY NETWORK, INC., 530 OLD WHITFIELD STREET, GUILFORD CT 06437
Michael A Boxer officer: Sr. VP and Gen. Counsel 168 THIRD AVENUE, WALTHAM MA 02451
Lisa P. Britt officer: Sr. VP and Chief HR Officer 168 THIRD AVENUE, WALTHAM MA 02451
Joseph R. Holmes officer: VP & Chief Accounting Officer 168 THIRD AVENUE, WALTHAM MA 02451
Michel Lagarde officer: Senior Vice President 450 LEXINGTON AVE., 31ST FLOOR, NEW YORK NY 10017
Stephen Williamson officer: Sr. VP and CFO 81 WYMAN STREET, WALTHAM MA 02451
Debora L Spar director C/O GOLDMAN, SACHS & CO., 200 WEST STREET, NEW YORK NY 10282
Jennifer M Johnson director C/O FRANKLIN RESOURCES, INC., ONE FRANKLIN PARKWAY, SAN MATEO CA 94403-1906
Jim P Manzi director 81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454
Ruby R Chandy director 630 DUNDEE ROAD, SUITE 400, NORTHBROOK IL 60062
Mark P Stevenson officer: Executive Vice President 850 LINCOLN CENTRE DRIVE, FOSTER CITY CA 94404
R. Alexandra Keith director ONE PROCTER & GAMBLE PLAZA, CINCINNATI OH 45202
Peter E Hornstra officer: Chief Accounting Officer 81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454
Syed A. Jafry officer: Sr. Vice President 345 E. MAIN STREET, WARSAW IN 46580